A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor

Proceedings of the National Academy of Sciences
2019.0

Abstract

<jats:title>Significance</jats:title> <jats:p> Agonists of the μ-opioid receptor (MOPr) are currently the gold standard for pain treatment. However, their therapeutic usage is greatly limited by side effects including respiratory depression, constipation, tolerance, and dependence. Functionally selective MOPr agonists that mediate their effects preferentially through G proteins rather than β-arrestin signaling are believed to produce fewer side effects. Here, we present the discovery of 3 unusual tetrapeptides with a unique stereochemical arrangement of hydrophobic amino acids from an Australian estuarine isolate of <jats:italic>Penicillium</jats:italic> species. Building on these natural templates we developed bilorphin, a potent and selective highly G protein-biased agonist of the MOPr. Further, through the addition of a simple sugar moiety, we generated bilactorphin that is an effective analgesic in vivo.

Knowledge Graph

Similar Paper

A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor
Proceedings of the National Academy of Sciences 2019.0
Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias
Journal of Medicinal Chemistry 2018.0
Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain
Journal of Medicinal Chemistry 2013.0
Progress in the development of more effective and safer analgesics for pain management
European Journal of Medicinal Chemistry 2019.0
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability
Journal of Medicinal Chemistry 2016.0
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity
Bioorganic &amp; Medicinal Chemistry 2014.0
Discovery of κ Opioid Receptor (KOR)-Selective <scp>d</scp>-Tetrapeptides with Improved In Vivo Antinociceptive Effect after Peripheral Administration
ACS Medicinal Chemistry Letters 2022.0
Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias
European Journal of Medicinal Chemistry 2022.0
Modulating β-arrestin 2 recruitment at the δ- and μ-opioid receptors using peptidomimetic ligands
RSC Medicinal Chemistry 2021.0
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1–13)-NH<sub>2</sub>
Journal of Medicinal Chemistry 2020.0